Verve Therapeutics, Inc.

NasdaqGS:VERV 주식 리포트

시가총액: US$991.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Verve Therapeutics 경영진

경영진 기준 점검 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Sek Kathiresan

최고경영자

US$7.4m

총 보수

CEO 급여 비율8.59%
CEO 재임 기간6yrs
CEO 지분 보유율0.8%
경영진 평균 재임 기간3.7yrs
이사회 평균 재임 기간4.2yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • Jun 17

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)

Summary Eli Lilly's $1.3B offer for Verve Therapeutics is a lifeline, providing a 70%+ premium and a solid exit for Verve investors. VERV struggled as a standalone due to tough gene therapy commercialization and competition from established cardiovascular treatments like statins and PCSK9 inhibitors. For LLY, the acquisition diversifies its pipeline and positions it for future innovation in chronic disease, despite high risk and uncertain payoff. The deal is mutually beneficial: Verve gets a strong exit, while Eli Lilly makes a speculative, forward-looking bet with its abundant cash reserves. Read the full article on Seeking Alpha
분석 기사 • May 28

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Verve Therapeutics, Inc. ( NASDAQ:VERV ) share price has dived 26% in the last...
분석 기사 • May 19

News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Apr 16

Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'

Summary VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102’s development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV’s pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly. And from a valuation perspective, the shares are cheaper than the first time I covered it. All while making great progress with its pipeline. So, ultimately, I think VERV remains a high-risk, long-term play in gene editing. But its risk-reward profile now seems to justify a “Buy” rating. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts

Summary Company received FDA IND clearance for VERVE-102 to treat HeFH, adding new trial sites in the United States. The switch to the Gal-NAc LNP delivery system aims to improve safety, avoiding clinical abnormalities observed with VERVE-101. Key upcoming catalysts include initial phase 1b Heart-2 data in Q2 2025, final dose-escalation data, and potential Eli Lilly opt-in for PCSK9 inhibitor program in the 2nd half of 2025. Atherosclerotic Cardiovascular Disease, in the 7 Major Markets, is expected to reach $30.6 billion by 2035. Read the full article on Seeking Alpha
Seeking Alpha • Feb 28

Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2

Summary Verve Therapeutics' stock remains a "Buy" despite recent setbacks, including the retirement of its Chief Medical Officer and the termination of a collaboration with Vertex. Verve's gene-editing programs aim to transform cardiovascular disease treatment by permanently lowering cholesterol through a one-time intravenous infusion, offering significant therapeutic and commercial potential. The upcoming data readout for Verve-102 in 2025 is crucial; success could attract Eli Lilly's partnership, while failure may question the entire base editing approach. Despite leadership changes and challenges, Verve's innovative approach and potential for groundbreaking treatments justify a high-risk, high-reward investment strategy. Read the full article on Seeking Alpha
분석 기사 • Dec 08

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 30

Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio

Summary Verve Therapeutics aims to revolutionize cardiovascular disease treatment with single-course gene editing, despite facing significant challenges and setbacks in clinical trials. The company's lead assets, VERVE-101 and VERVE-102, target the PCSK9 gene to lower LDL-C levels, but safety issues have hindered progress. Verve-102, using a different delivery technology, is now the focus, with initial data expected in 1H25, presenting a crucial milestone for investors. Partnerships with Eli Lilly, Beam Therapeutics, and Vertex offer potential financial support and validation, but Verve remains a high-risk, high-reward investment. Read the full article on Seeking Alpha
분석 기사 • Aug 10

Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

As you might know, Verve Therapeutics, Inc. ( NASDAQ:VERV ) just kicked off its latest second-quarter results with some...
분석 기사 • Jul 12

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jun 13

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Summary Verve Therapeutics focuses on gene editing technology for one-dose therapies to reduce lipid levels related to ASCVD. VERV's pipeline includes therapies targeting genes like PCSK9, ANGPTL3, and LPA to lower ASCVD risk. Verve's leading programs, VERVE-101 and VERVE-102, target heterozygous familial hypercholesterolemia (HeFH), with VERVE-101 in clinical trials and VERVE-102 in the IND-enabling stage. Financially, Verve has a strong cash position, with $606.3 million in liquidity and a cash runway of approximately 3.5 years. VERV's research is in the early stages, making it a speculative investment, but it is worth adding to a watchlist as research progresses. Read the full article on Seeking Alpha
분석 기사 • May 14

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...
분석 기사 • May 12

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

As you might know, Verve Therapeutics, Inc. ( NASDAQ:VERV ) just kicked off its latest first-quarter results with some...
Seeking Alpha • Apr 03

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Summary Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despite VERVE-101 setback, the ability to move forward with another PCSK9 inhibitor known as VERVE-102 where the phase 1b heart-2 study is expected to begin any day now in Q2 2024. VERVE-102 could be a major change in structure because it has two distinct features compared to its predecessor, which are a different ionizable lipid and the GalNAc delivery system. Partnership with Eli Lilly remains in place for now, despite VERVE-101 enrollment being paused. Read the full article on Seeking Alpha
분석 기사 • Feb 28

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 13

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Summary Verve Therapeutics aims to revolutionize cardiovascular disease treatment with gene therapy. Recent VERVE-101 data shows LDL-C reduction comparable to existing drugs but with serious adverse events in two patients, raising safety concerns. Verve's financials show a solid runway with ~$600 million in liquid assets after a recent capital infusion, but ongoing and future trials will demand substantial funding. Recommendation: Sell. Despite proof-of-concept and a one-time treatment appeal, safety concerns and competitive landscape challenge its long-term valuation. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Vectoring In On Verve Therapeutics

Summary Verve Therapeutics aims to revolutionize treatment for cardiovascular disease through in vivo gene therapy using base editing technology. Their lead candidate, VERVE-101, has shown promising results in reducing LDL-C levels in preclinical studies. Verve has partnerships with Beam Therapeutics, Eli Lilly, and Vertex Pharmaceuticals, and analysts have a positive outlook on the company. A full investment analysis around Verve Therapeutics stock is presented in the paragraphs below. Read the full article on Seeking Alpha
분석 기사 • Jun 07

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
분석 기사 • Feb 24

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Nov 09

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 20

Verve Therapeutics: Cathie Wood Adds To ARKK

Summary ARKG component added to flagship fund. Meaningful position would top 7% of outstanding shares. Company fits usual pattern with large losses and cash burn.

CEO 보수 분석

Sek Kathiresan의 보수는 Verve Therapeutics의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Mar 31 2025n/an/a

-US$181m

Dec 31 2024US$7mUS$639k

-US$199m

Sep 30 2024n/an/a

-US$197m

Jun 30 2024n/an/a

-US$193m

Mar 31 2024n/an/a

-US$197m

Dec 31 2023US$9mUS$597k

-US$200m

Sep 30 2023n/an/a

-US$193m

Jun 30 2023n/an/a

-US$192m

Mar 31 2023n/an/a

-US$179m

Dec 31 2022US$8mUS$571k

-US$157m

Sep 30 2022n/an/a

-US$148m

Jun 30 2022n/an/a

-US$125m

Mar 31 2022n/an/a

-US$137m

Dec 31 2021US$6mUS$519k

-US$120m

Sep 30 2021n/an/a

-US$113m

Jun 30 2021n/an/a

-US$99m

Mar 31 2021n/an/a

-US$53m

Dec 31 2020US$2mUS$480k

-US$46m

보상 대 시장: Sek의 총 보수(USD7.44M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.54M)보다 높습니다.

보상과 수익: Sek의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Sek Kathiresan (53 yo)

6yrs
재임 기간
US$7,442,663
보수

Dr. Sekar Kathiresan, M.D., also known as Sek, is Independent Non-Employee Director of Maze Therapeutics, Inc. He is Independent Director at Relay Therapeutics, Inc. since July 2022. He Co-Founderd at Maze...

리더십 팀

이름직위재임 기간보수지분
Burt Adelman
Co-Founder & Independent Chairman of the Board7.4yrsUS$569.00k0.48%
$ 4.8m
Sekar Kathiresan
Co-Founder6yrsUS$7.44m0.78%
$ 7.8m
Andrew Ashe
President6.9yrsUS$2.38m0.39%
$ 3.9m
Allison Dorval
CFO & Principal Accounting Officer3.7yrsUS$2.88m0.015%
$ 147.4k
Kiran Musunuru
Co-Founderno data데이터 없음데이터 없음
J. Joung
Co-Founderno data데이터 없음데이터 없음
Anthony Philippakis
Co-Founder & Scientific Advisory Board Memberno dataUS$7.97k데이터 없음
Barry Ticho
Co-Founderno data데이터 없음데이터 없음
Issi Rozen
Co-Founder & Strategic Advisorno data데이터 없음데이터 없음
Troy Lister
Chief Scientific Officer1.1yrs데이터 없음0.0078%
$ 77.1k
Joan Nickerson
Chief Administrative Officer2.4yrs데이터 없음0.019%
$ 193.3k
Jennifer Robinson
Senior Vice President of Investor Relations & Corporate Communications3.7yrs데이터 없음데이터 없음
3.7yrs
평균 재임 기간
57yo
평균 나이

경험이 풍부한 관리: VERV의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.7 년).

이사회 구성원

이름직위재임 기간보수지분
Burt Adelman
Co-Founder & Independent Chairman of the Board7.4yrsUS$569.00k0.48%
$ 4.8m
Sekar Kathiresan
Co-Founder6yrsUS$7.44m0.78%
$ 7.8m
Anthony Philippakis
Co-Founder & Scientific Advisory Board Member3.8yrsUS$7.97k데이터 없음
Daniel Rader
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Eugene Braunwald
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Michael MacLean
Independent Director4.2yrsUS$534.00k0%
$ 0
Sheila Mikhail
Independent Director4.3yrsUS$526.50k0%
$ 0
Lonnel Coats
Independent Director2.9yrsUS$521.50k0%
$ 0
Jodie Morrison
Independent Director1.1yrsUS$964.97k0%
$ 0
Krishna Yeshwant
Independent Director6.9yrsUS$522.67k0%
$ 0
Alexander Cumbo
Independent Director3.1yrsUS$521.50k0%
$ 0
Andrew Geall
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
4.2yrs
평균 재임 기간
56yo
평균 나이

경험이 풍부한 이사회: VERV의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.2 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2025/07/24 14:38
종가2025/07/24 00:00
수익2025/03/31
연간 수익2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Verve Therapeutics, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Andrea NewkirkGoldman Sachs
Mitchell KapoorH.C. Wainwright & Co.
Dae Gon HaStifel, Equities Research